AI Article Synopsis
- The incidence of epilepsy increases with age, particularly from 50 to 75 years, with late-onset epilepsy showing different characteristics compared to early-onset cases.
- The study focused on patients aged 50 and older who had epilepsy, analyzing treatment responses over an average follow-up period of 2.8 years.
- Results indicated that most patients responded well to a single antiseizure medication, with a low and stable rate of drug-resistant epilepsy over time.
Article Abstract
Background: The annual incidence of epilepsy increases with age, from nearly 28 per 100,000 by the age of 50 years to 139 per 100,000 by the age of 75 years. Late-onset epilepsy differs from epilepsy at a young age in the prevalence of structural-related epilepsy, types of seizures, duration of seizures, and presentation with status epilepticus.
Objectives: To check the response to treatment in patients with epilepsy with age of onset of 50 years and older.
Methods: We conducted a retrospective study. The cohort included all patients referred to the Rambam epilepsy clinic between 1 November 2016 and 31 January 2018 with epilepsy onset at age 50 years or older and at least one year of follow-up at the recruitment time point and epilepsy not caused by a rapidly progressive disease.
Results: At recruitment, most patients were being treated with a single antiseizure medication (ASM); 9 of 57 patients (15.7%) met the criteria for drug-resistant epilepsy (DRE). The mean duration of follow-up was 2.8 ± 1.3 years. In an intention-to-treat analysis, 7 of 57 patients (12.2%) had DRE at the last follow-up.
Conclusions: Late-onset epilepsy, which is defined as a first diagnosis in patients older than 50 years of age, is easy to control with monotherapy. The percentage of DRE in this group of patients is relatively low and stable over time.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Management and outcomes among older adults with generalized epilepsy in routine clinical practice.
Epilepsia Open
December 2024
Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Generalized epilepsy is classically thought of as a disease of the young and adolescent, with rarely reported cases among older adults. We aimed to analyze management and outcomes in a population sparsely described in the literature through a retrospective single-center cohort design. After excluding individuals without follow-up, we identified 151 people ≥50 years at the time of electrographically confirmed generalized epilepsy.
View Article and Find Full Text PDFLate onset epilepsy findings in a developmental country, a report of first results.
Epilepsy Res
December 2024
Neurology dapartment, faculty of medicine, Cairo university, Egypt. Electronic address:
Introduction: Older patients with Late onset epilepsy (LOE) provide a special set of difficulties for both the treating doctors and the patients.
Objectives: To address the characteristics and treatment outcomes of LOE in a cohort of Egyptian population at a tertiary center and to assess factors affecting seizure freedom in this age group.
Methods: From December 1, 1995, to November 30, 2020, we analysed all patients with newly diagnosed epilepsy above the age of 50 at Cairo University's neurology department.
Prevalance of Non-Provoke Generalize Tonic-Clonic Seizure in Sporadic Alzheimer's Disease.
J Epilepsy Res
December 2024
Department of Neurology, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Background And Purpose: Alzheimer's disease (AD) and epileptic seizure are among the most common health problems in the elderly population. This study aimed to estimate the prevalence rate and predictors of seizures in sporadic AD patients.
Methods: The study was conducted by retrospectively for a period of 10 years examining the file records.
Adult-onset status epilepticus in patients with COQ8A coenzyme Q10 deficiency: A case series.
Epilepsy Behav Rep
October 2024
Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.
This case series describes the clinical features, diagnostic challenges, treatment approaches, and outcomes of three adult patients with COQ8A-related CoQ10 deficiency presenting with focal status epilepticus, who were effectively treated at the Department of Neurology, Philipps University Marburg, Marburg, Germany. The patients, all from consanguineous families with the first two being siblings, presented with a late onset of the disease, characterized by progressive cerebellar ataxia and epilepsy, with clinical deterioration and focal status epilepticus occurring in adulthood. The first patient exhibited myoclonic status, while the second and third patients presented with bilateral tonic-clonic seizures followed by focal status epilepticus manifesting with cortical blindness.
View Article and Find Full Text PDFRORA-neurodevelopmental disorder: a unique triad of developmental disability, cerebellar anomalies, and myoclonic seizures.
Genet Med
December 2024
Genetics Department, Hospices Civils de Lyon, Lyon, France; Neuromyogene Institute, Pathology and Genetics of neuron and muscle, CNRS UMR 5261 INSERM U1315, University of Lyon - Université Claude Bernard Lyon 1, Lyon, France. Electronic address:
Article Synopsis
- RORA is a gene linked to the development and function of the cerebellum, and this study explores the largest group of individuals with RORA-related neurodevelopmental disorders (RORA-NDD).
- The study involved 40 participants with various pathogenic variants of RORA, revealing a range of clinical features including developmental and intellectual disabilities, as well as cerebellar symptoms that can vary in onset and severity.
- Findings indicate that certain missense variants are associated with more severe cerebellar issues, and common elements of RORA-NDD include developmental disabilities, cerebellar symptoms, and different types of myoclonic epilepsy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!